Bizelesin

Drug Profile

Bizelesin

Alternative Names: NSC 615291; U 77779

Latest Information Update: 11 Aug 2009

Price : $50

At a glance

  • Originator Pfizer
  • Class Indoles; Pyrroles; Small molecules
  • Mechanism of Action Alkylating agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
  • 01 Aug 2002 A phase I study has been added to the Cancer therapeutic trials, adverse events and pharmacokinetics sections
  • 05 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top